FDA Resurrects Park Doctrine in Enforcement of Pharmaceutical GMPs
This article was originally published in The Gold Sheet
FDA is following through on earlier threats to dust off the long-dormant Park doctrine for holding chief executive officers of pharmaceutical companies personally accountable for manufacturing problems.
You may also be interested in...
CDER Pharmaceutical Quality Office Gains Permanent Director
Former Novartis exec to join FDA in November.
KV Official Is Excluded From Government Programs, The First Under OIG's New Guidance
Former CEO Marc Hermelin resigns from KV's board to prevent the company's exclusion; KV dissolved Ethex under agreement with OIG.
J&J Faces Possible Criminal Liability As Post-Recall Overhaul Continues
FDA could seek misdemeanor charges against J&J officers under the Park Doctrine, which can be invoked against executives who could have prevented adulteration or misbranding of a drug. California Republican Issa says regardless whether criminal indictments come, the case "could be fair warning" to other firms regarding quality system failures.